Technology | Magnetic Resonance Imaging (MRI) | December 19, 2017

Toshiba Medical Launches Galan RT Solutions for MRI Radiation Therapy Planning

New tools for Vantage Galan 3T MRI integrate third-party technologies for enhanced patient positioning, tumor targeting

Toshiba Medical Launches Galan RT Solutions for MRI Radiation Therapy Planning

December 19, 2017 — Toshiba Medical, a Canon Group company, introduced the Galan RT Solutions suite of radiation therapy tools, available on the premium Vantage Galan 3T magnetic resonance imaging (MRI) system at the 2017 Radiological Society of North America (RSNA) Annual Meeting, Nov. 26-Dec. 1 in Chicago. Galan RT Solutions allow healthcare providers to precisely map MR data to positron emission tomography (PET)/computed tomography (CT) images to develop confident plans for radiation therapy.

The all-new Galan RT Solutions include the advanced Universal Couchtop MR Overlay from Civco Radiotherapy to aid clinicians in accurately determining the treatment target area, helping to improve patient safety by sparing healthy tissue from unnecessary radiation. The fiberglass and foam couchtop overlay core offers a high degree of stability for the head, neck and shoulders, and Prodigy 2 indexing at 7 cm increments to help physicians seamlessly transfer from imaging to treatment. A Three-Pin Lok-Bar offers providers the option to use existing MR-compatible devices by indexing them to the overlay, while adjustable ATLAS body coil technology allows clinicians to combine coils for extended patient coverage and enhanced workflow. Galan RT Solutions are rounded out with the optional MR Laser from LAP Laser and Mirada RTx Fusion software, which enable providers to achieve precise patient marking, accurate treatment planning and exact positioning for successful treatment.

For more information: www.medical.toshiba.com

Related Content

Stronger Distribution Networks to Bolster Radiotherapy Patient Positioning Accessories
News | Patient Positioning Radiation Therapy | July 19, 2019
A recent study projects global market revenues for radiotherapy patient positioning accessories will exceed revenues of...
Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Feature | Contrast Media | July 18, 2019 | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n
CMS Proposes New Alternative Payment Model for Radiation Oncology
News | Radiation Oncology | July 17, 2019
The Centers for Medicare and Medicaid Services (CMS) issued a proposal for an advanced alternative payment model (APM)...
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
RaySearch Releases Version 3A of RayCare Oncology Information System
Technology | Oncology Information Management Systems (OIMS) | July 15, 2019
RaySearch has released RayCare 3A, a new version of the next-generation oncology information system (OIS). RayCare is...
FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...
Insightec's Exablate Neuro Approved With GE Signa Premier MRI in U.S. and Europe
News | Focused Ultrasound Therapy | July 10, 2019
GE Healthcare and Insightec announced U.S. Food and Drug Administration (FDA) approval and CE mark for Insightec’s...